What is the DSCSA? US prescription drug traceability explained
How the US tracks prescription medicines through the supply chain, and why that matters when a medicine is shipped to you.
Reviewed by the Reserve Meds clinical operations team on 17 October 2026. Sources accessed 17 October 2026.
The short answer
The Drug Supply Chain Security Act (DSCSA) is the US law that builds an electronic, interoperable system to identify and trace certain prescription drugs at the package level as they move through the supply chain. It aims to keep harmful drugs out, detect them if they enter, and remove them fast. For patients abroad, it means a US-sourced medicine can be traced back through licensed trading partners.
- What it is: A US federal law on prescription drug supply chain security.
- Core idea: Package-level identification and tracing.
- Duties include: Prompt notice to FDA of illegitimate product; annual licensure reporting.
- Current exemption: Small dispensers until 27 November 2027.
What the DSCSA does
FDA describes the DSCSA as outlining steps to achieve an interoperable, electronic way to identify and trace certain prescription drugs at the package level as they move through the supply chain. This helps prevent harmful drugs from entering the US supply chain, detect them if they do, and enable rapid response to remove them.[1]
What trading partners must do
- Notify FDA within twenty-four hours after determining that a product is illegitimate.[1]
- Wholesale distributors and third-party logistics providers report licensure and other information to FDA every year.[1]
- Exchange information with FDA and other trading partners through the DSCSA portal.[1]
- Request a waiver, exception or exemption from certain requirements where they cannot comply.[1]
Where implementation stands in 2026
FDA has exempted small dispensers, such as pharmacies, and where applicable their trading partners, from certain section 582 requirements until 27 November 2027, to finish its assessment of small dispensers. For this exemption, a small dispenser is one whose owning company has 25 or fewer full-time licensed pharmacists or pharmacy technicians as of 27 November 2026. Trading partners that do not qualify and cannot meet the enhanced requirements may request a waiver.[2]
Why it matters for patients outside the US
A medicine bought outside licensed channels has no reliable history. A medicine bought from a licensed US wholesale distributor sits inside a system built to trace packages and flag illegitimate products.
WHO warns that substandard and falsified medicines are often sold online or in informal markets. Traceability is one of the strongest protections against them.[3]
FDA does not issue export certificates for medicines exported for an individual's personal use; the importing country's regulator sets the import documents.[4]
What to ask your supplier
- Which licensed US distributor is the source of the product?
- What are the batch number and expiry date, and will they appear on the invoice?
- Can you provide the shipping and temperature record for the delivery?
Reserve Meds supplies through a US-licensed pharmaceutical wholesale partner and gives the receiving hospital the batch and shipping documents.
The DSCSA and medicines shipped abroad
FDA treats exports of human drugs for an individual's personal use as outside the Federal Food, Drug, and Cosmetic Act's export provisions and does not issue export certificates for them. Commercial exports fall under FDA's purview, and the importing country decides which documents it needs.[4]
For a named-patient supply to a hospital abroad, the practical protection is that the medicine is bought from a licensed US distributor inside the DSCSA system, with batch and shipping records the receiving hospital can check.
Two dates worth knowing
- Trading partners must notify FDA within twenty-four hours after determining that a product is illegitimate.[1]
- FDA's exemption from certain requirements for small dispensers runs until 27 November 2027.[2]
How Reserve Meds helps
Reserve Meds is a digital health company. Medicines are supplied through a US-licensed pharmaceutical wholesale partner. We help families and treating doctors understand the route, prepare the documents the regulator or hospital asks for, arrange supply from the US once approval is in place, and keep everyone updated. We do not diagnose, prescribe or decide what a regulator approves.
We coordinate access to FDA-approved medicines only. Investigational medicines are only available through a manufacturer's expanded-access program requested by the treating physician; we can explain that route, but we do not supply them. Your coordination fee is quoted in writing for your case before you commit. No hidden charges. We give you a written timeline estimate for your case before you commit.
Ask us about a medicine
Tell us the medicine, your country and a WhatsApp or phone number. We reply within one business day. On WhatsApp we usually reply the same day.
Frequently asked questions
What does DSCSA stand for?
The Drug Supply Chain Security Act, a US law on identifying and tracing certain prescription drugs through the supply chain.
How fast must a trading partner tell FDA about an illegitimate product?
Within twenty-four hours after determining the product is illegitimate.
Are any businesses still exempt in 2026?
Yes. FDA exempted small dispensers, and where applicable their trading partners, from certain requirements until 27 November 2027.
Does the DSCSA apply in my country?
No. It is a US law covering the US supply chain. It matters abroad because a medicine sourced from licensed US distributors has a traceable history.
Sources for these answers: [1, 2]
Sources
All sources were opened and checked on 17 October 2026. Rules and labels change, so the treating hospital or regulator confirms the current position before anything is filed.
- US FDA: Drug Supply Chain Security Act (DSCSA) (accessed 17 October 2026)
- US FDA: Exemptions under the Drug Supply Chain Security Act (small dispensers until 27 November 2027) (accessed 17 October 2026)
- World Health Organization: Substandard and falsified medical products (fact sheet) (accessed 17 October 2026)
- US FDA: Export Requirements for Human Drugs (accessed 17 October 2026)
Related
- Fake and substandard medicines
- Cold-chain medicines
- Answers to common access questions
- Named-patient access, explained
- US expanded access (compassionate use)
This page is general information, not medical or legal advice. It does not replace advice from your own doctor or the regulator.